Our team had a wonderful time at #WCIRDC24, where we expressed support for endocrinologists and presented encore data on our PALISADE: Phase 3 Study evaluating our investigational #RNAi medicine for Familial Chylomicronemia Syndrome (FCS) treatment. Learn more: https://bit.ly/49vP9Gj
Arrowhead Pharmaceuticals
Biotechnology Research
Pasadena, California 46,295 followers
About us
At Arrowhead Pharmaceuticals we are breaking the mold of medicine. We are pushing the boundaries of therapeutic development and revolutionizing how we care for hard-to-treat illnesses. As a company we harness collaboration and innovation to rapidly advance drugs from discovery to the clinic. All applicants: Please be aware of employment scams using Arrowhead’s name and the names of Arrowhead’s employees. All job related Arrowhead communication should come from the domain @arrowheadpharma.com.
- Website
-
http://www.arrowheadpharma.com
External link for Arrowhead Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Pasadena, California
- Type
- Public Company
- Specialties
- Biotech, Drug Development, Pharmaceuticals, and RNAi
Locations
-
Primary
Get directions
177 E Colorado Blvd
Suite 700
Pasadena, California 91105, US
-
Get directions
502 S Rosa Rd
Madison, Wisconsin 53719, US
-
Get directions
10102 Hoyt Park Drive
San Diego, CA 92131, US
-
Get directions
1080 Arrowhead Way
Verona, WI 53593, US
Employees at Arrowhead Pharmaceuticals
Updates
-
At the APA/JPS/CAP/IAP 2024 Annual Meeting, we shared encore data on our investigational #RNAi medicine for treatment of Familial Chylomicronemia Syndrome (FCS). We were thrilled to support and partner with industry leaders to raise awareness for triglyceride induced acute pancreatitis. Check out the photos below to see our team in action! Learn more: https://bit.ly/3Zotiw5
-
-
Today we announced interim results from a Phase 1/2a clinical study of ARO-CFB, our investigational #RNAi therapeutic being developed as a potential treatment for complement mediated diseases. Read more in our press release: https://bit.ly/3Pbos0B
-
-
Today we announced we have filed a request for regulatory clearance to initiate a Phase 1/2a Study of ARO-ALK7, our second #RNAi therapy being developed as a potential treatment for obesity. Read more in our press release: https://bit.ly/4geq0C9
-
-
Ending the year off strong- we are attending and presenting at several conferences this December. See you there! Learn more here: https://bit.ly/3ZwsvdK
-
-
Yesterday we reported our fiscal 2024 year end results. Watch a replay of our webcast and read more in our press release: https://bit.ly/3VebYsb
-
-
We announced a partnership with Sarepta Therapeutics to advance #GeneticMedicine programs in rare diseases of the muscle, CNS, and the lungs. We look forward to a long-term collaboration that provides hope to patients with significant unmet needs. Learn more here: https://bit.ly/4g4I6Xh
-
-
Today, we announced the submission of a New Drug Application (NDA) to the FDA for our investigational #RNAi medicine for treatment of familial chylomicronemia syndrome (#FCS). We plan to submit applications for approval to additional regulatory authorities in 2025. Learn more: https://bit.ly/40OlfuR
-
-
We’re here at the American Heart Association’s Scientific Sessions in Chicago. Find us at booth 1717 and let’s reimagine what’s possible for people with extremely high triglycerides. #AHA24 LowerTriglycerides.com
-